Indian Immunologicals Ltd. (IIL), headquartered in Hyderabad, India, is one of the largest and most respected producers of veterinary and human vaccines in South Asia. Established in 1982 by the National Dairy Development Board (NDDB), IIL was founded with the mission to make vaccines affordable and accessible for both animals and humans, particularly in developing regions. Over four decades, the company has emerged as a global leader in immunological solutions that support public health, livestock productivity, and disease eradication efforts.
Operating across more than 50 countries, Indian Immunologicals Ltd. integrates world-class R&D, WHO-GMP compliant manufacturing, and an extensive distribution network to deliver high-quality biologicals that impact millions of lives.
Core Business
IIL’s core business spans the development, production, and marketing of:
- Veterinary Biologicals (vaccines and diagnostics)
- Human Vaccines (including rabies, hepatitis, and pediatric vaccines)
- Animal Health Products (biologicals and formulations)
- Contract Manufacturing and Technology Transfer Projects for public and private entities globally
IIL serves a wide range of customers including livestock farmers, pet owners, public health institutions, and pharmaceutical companies.
Product and Service Offerings
Veterinary Vaccines and Biologicals
- Raksha-Ovac – Foot-and-Mouth Disease (FMD) vaccine, pivotal to India’s FMD control program
- Bruvax – Brucellosis vaccine for bovine health
- Rakshavac-T – Theileriosis vaccine for cattle
- Pestiguard – Peste des Petits Ruminants (PPR) vaccine for goats and sheep
- Megavac-6 – Canine vaccine offering protection against six major infectious diseases
Human Vaccines
- Abhayrab – WHO prequalified purified Vero cell rabies vaccine for intradermal and intramuscular use
- Abhayflu, Hepavax, and other immunization products for public and private healthcare
IIL also provides cold chain logistics, technical training, and disease surveillance programs in partnership with governments and NGOs.
Specialisation and Core USP
Indian Immunologicals is known for its high-volume, low-cost vaccine production model supported by advanced scientific infrastructure. Its core USPs include:
- World’s largest producer of veterinary vaccines for FMD and rabies
- Over 70% market share in India for key veterinary vaccines
- First Indian company to launch a tissue culture rabies vaccine (Abhayrab)
- State-of-the-art manufacturing campuses in Hyderabad and Ooty
- Expertise in both live and inactivated vaccine production
Their vertically integrated operations ensure cost efficiency, quality assurance, and scale unmatched by many global peers.
Financials
Though not publicly listed, IIL’s financial performance is robust, supported by market leadership and global demand. Key indicators include:
- Revenue exceeding INR 800 crores (approx. USD 100 million) in FY2022
- Export presence in over 50 countries, including Southeast Asia, Africa, Latin America, and the CIS
- Supplied vaccines to national immunization programs in multiple countries
- Investment in building a new human vaccine manufacturing facility with over INR 75 crore earmarked for expansion
The company consistently reinvests in R&D and infrastructure to maintain leadership in biologicals.
Shipments and Usage Metrics
From trade and institutional data:
- Over 400 million doses of veterinary vaccines produced annually
- Supplied more than 30 million doses of rabies vaccine for human use
- A key supplier in India’s FMD Control Programme (FMDCP), contributing to dramatic reductions in outbreaks
- Large-scale provider to government tenders, including UNICEF and PAHO
IIL has the capacity to deliver over 1 billion doses annually across its human and animal health product lines.
Target Market
Indian Immunologicals serves a wide and diverse customer base:
- Livestock farmers and veterinary networks
- Public health agencies and immunization programs
- Animal husbandry departments and cooperatives
- International health organizations (WHO, FAO, OIE)
- Distributors, wholesalers, and NGOs
Their mission-driven approach makes them a preferred supplier in developing nations, where cost-effective and reliable vaccines are crucial.
Capabilities
- Multiple WHO-GMP certified manufacturing sites
- Dedicated R&D centers for both human and animal vaccines
- Cold chain infrastructure for temperature-sensitive logistics
- Veterinary field support and training teams
- In-house diagnostics and quality control systems
IIL is also active in contract manufacturing, offering fill-finish and bulk supply services to global vaccine producers.
Certifications and Compliance
- WHO-GMP certified manufacturing units
- ISO 9001 and ISO 14001 certifications
- WHO prequalification for rabies vaccine (Abhayrab)
- Approved by DCGI (India) and international regulatory authorities in over 25 countries
- Compliant with OIE guidelines for veterinary vaccines
Their facilities undergo regular audits by global clients and international health agencies.
Customer Testimonials
- "We’ve used Raksha vaccines for over a decade. They’re dependable, effective, and supported by good field teams." – District Veterinary Officer, Uttar Pradesh
- "Abhayrab is cost-effective and reliable. It plays a crucial role in our public health anti-rabies drive." – Public Health Coordinator, Philippines
Major Achievements
- Among the world's top three manufacturers of rabies vaccine
- Key player in India’s National Animal Disease Control Program (NADCP)
- Developed India’s first indigenous brucellosis vaccine
- Consistently ranked among India’s top 10 biotech companies
- Export partnerships with governments and global health organizations
- Continues to lead in new vaccine development, including a Covid-19 vaccine platform in collaboration with Griffith University, Australia
Indian Immunologicals Ltd. exemplifies innovation, affordability, and public health commitment in the vaccine industry. With its blend of scientific excellence and mission-driven operations, IIL remains a cornerstone in the global fight against infectious diseases in animals and humans.
